Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6656998 | 0.91 | MAPT (0.52) | MEN1KMT2ANPC1MAPTHPGD | |
| SCHEMBL31186730 | 0.88 | MEN1 (0.52) | MEN1KMT2ANPC1MAPTHPGD | |
| SCHEMBL6113275 | 0.88 | MEN1 (0.52) | MEN1KMT2ANPC1MAPTHPGD | |
| SCHEMBL6113265 | 0.87 | KMT2A (0.51) | MEN1KMT2ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL27660170 | 0.84 | TP53 (0.51) | MEN1KMT2ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL28401250 | 0.83 | LMNA (0.42) | MEN1KMT2ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL27999 | 0.82 | NPC1 (0.58) | MEN1KMT2ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL30947366 | 0.82 | NPC1 (0.58) | MEN1KMT2ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL28407096 | 0.81 | MEN1 (0.41) | MEN1KMT2ANPC1TSHRRAB9A | |
| SCHEMBL28552669 | 0.80 | TSHR (0.56) | MEN1KMT2ANPC1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111234070-B | Catalyst component, catalyst system and prepolymerized catalyst for olefin polymerization, use thereof and olefin polymerization process | 中国石油化工股份有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-111234073-B | Catalyst component, catalyst system and prepolymerized catalyst for olefin polymerization, use thereof and olefin polymerization process | 中国石油化工股份有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-111234070-A | Catalyst component, catalyst system and prepolymerized catalyst for olefin polymerization, use thereof and olefin polymerization process | 中国石油化工股份有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-111234073-A | Catalyst component, catalyst system and prepolymerized catalyst for olefin polymerization, use thereof and olefin polymerization process | 中国石油化工股份有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-111234070-B | Catalyst component, catalyst system and prepolymerized catalyst for olefin polymerization, use thereof and olefin polymerization process | 中国石油化工股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-111234073-B | Catalyst component, catalyst system and prepolymerized catalyst for olefin polymerization, use thereof and olefin polymerization process | 中国石油化工股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-111234070-A | Catalyst component, catalyst system and prepolymerized catalyst for olefin polymerization, use thereof and olefin polymerization process | 中国石油化工股份有限公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-111234073-A | Catalyst component, catalyst system and prepolymerized catalyst for olefin polymerization, use thereof and olefin polymerization process | 中国石油化工股份有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-2757102-B1 | Intermediate for producing a cyclic sulfonic acid ester | WAKO PURE CHEM IND LTD (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-8969591-B2 | Method for producing cyclic sulfonic acid ester and intermediate thereof | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| EP-2463281-B1 | METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF | WAKO PURE CHEM IND LTD (JP) | 2014-10-22 | — | — | EP | disclosed |
| EP-2757102-A1 | 1,3-propanesultone derivative useful in the preparation of a 1,3-propenesultone derivative | Wako Pure Chemical Industries, Ltd. (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-20140142324-A1 | METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-8673963-B2 | Method for producing cyclic sulfonic acid ester and intermediate thereof | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2463281-A1 | METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF | Wako Pure Chemical Industries, Ltd. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120130089-A1 | METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142324-A1 | METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF | STS, TST, SULT1A1 | MEN1 3976/4885KMT2A 2802/4885NPC1 4217/4885 |
| US-20120130089-A1 | METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF | STS, TST, SULT1A1 | MEN1 3976/4885KMT2A 2802/4885NPC1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.